Good company judging by the company's performance and stock trend. Rolled back to the area 30% on the news about the vaccine Quarterly reporting will be February 2, 2021. If vaccination does not show significant benefits and the company's revenues continue to grow, it is possible that the shares will be bought back.
What do you think about the shares of this company?
Trade aktif
Consolidation is broken upwards.
Catatan
Option Finder:
Long Call: Buy 1x 15th Oct $590,00 Call @ $4,10 Entry cost: $410,00 (debit) Maximum risk1: $410,00 Est. return1 at target price: $3 590,00 (875.6%)
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.